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We welcome the opportunity to correct several mis-
leading claims by the correspondent in relation to our
article “Methods for integrating medication compli-
ance and persistence in pharmacoeconomic evalua-
tions” (Value in Health 2007;10:498–509).
The correspondent notes that the speciﬁcation of
the net-beneﬁt regression we presented in our article
does not allow for the assessment of population cost-
effectiveness. We erroneously included the word
“population,” which should have read “individual,”
as stated earlier in the same sentence, namely, “The
advantage of this approach is that the impact of com-
pliance on cost-effectiveness may be assessed at an
individual patient level . . .”
It appears that the correspondent understands the
net-beneﬁt regression to be a real example, by asking
whether or not the equation on page 506 refers to the
full model, and for details of the -2 log likelihood
ratio and the chi-square statistics. This is very curious
given that the equation presented is merely for
illustration.
With regard to the advantages and disadvantages of
net-beneﬁt regression analyses, readers should refer to
more authoritative text as referenced in the manu-
script; our article was not intended to include a
detailed account of net-beneﬁt regression.
The correspondent implies that in our illustrative
Markov model, patients die many times, as a curly
arrow is used for the death state. It is naive in the
extreme to suggest that this occurred in our analysis.
The presence of arrows represents a transition prob-
ability greater than 0. The important point is that
death is treated as an absorbing state, and this is cer-
tainly the case in the analysis presented.
The correspondent states that the model must con-
sider the returning process from progressive to remis-
sive. There is no reason why there should necessarily
be a reverse arrow representing this transition. For a
noncurable disease with no prospects of remission
(and of course there are several such examples), then
the transition probability of moving from “progres-
sive” to “remissive” is zero. The purpose of the hypo-
thetical example was not to represent any speciﬁc
disease or treatment, but to illustrate how the analyst
may incorporate persistence in a Markov modelling
framework.
The correspondent questions the transparency of
our model. The data included in Table 2, together with
the referenced data on age-standardized life-table
probabilities, are sufﬁcient for an interested reader to
replicate the model and results in full. It is important to
note the following:
1. This is a hypothetical example, but the correspon-
dent asks for some justiﬁcation of the transition
probabilities, suggesting that he perhaps considers
this to be a real example too.
2. The correspondent does not appear to notice that
(besides the data in Table 2), the model also used
(referenced) age-standardized life-table probabili-
ties for mortality. If these were all presented in the
article as a set of transition probability matrices,
then it would obfuscate the intended purpose of
the article.
3. In Table 2 it is very clear that persistence is pre-
sented as a probability, i.e., the probability of
patients persisting at 5 years is 0.6. This is consis-
tent with standard reporting of events that occur
over time [1]. Calculating a 1-year probability is
very simple (= 5-year probability raised to the
power of 1/5).
4. The analysis was conducted in Microsoft Excel.
A “special” software is clearly not required to
perform a simple Markov model as described in
the article.
In the interests of transparency, we have made
the model available from: http://www.bangor.ac.uk/
~pss037/Model.xls
We hope that these explanations clarify the model
and analyses reported in our article.––Dyfrig Hughes,
MSc, PhD, MRPharmS, IMSCaR Bangor University,
North Wales, UK; Warren Cowell, MSc, BSc, Roche,
Welwyn Garden City, Herts, UK; Tamas Koncz, MD,
MSc, Bristol Myers Squibb, Rueil-Malmaison, France;
Joyce Cramer, BS, Yale University, New Haven, CT,
USA.
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